CLAIMS

1. A compound of Formula I:

A-B

its prodrug forms, or pharmaceutically acceptable salts thereof, wherein

A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure substituted with R^6, R^7, R^8, R^9, and R^{20};

B represents



or



;

R^1 represents OH, halogen, COOH, COO-C_{1-4} alkyl, O-$(CH_2)_{0-1}$-Ph, $N(R^{10})_2$, CH_2OR^{10}, C_{1-6} halogenated alkyl, O-$(CH_2)_{1-4}$-CO-$N(R^{10})_2$, SC_{1-4} alkyl, $NHSO_2C_{1-4}$alkyl, SO_2-OH, O-SO_2-OH, O-SO_2-O-C_{1-4} alkyl, $OP(O)(OH)_2$, or OPO_3C_{1-4} alkyl;

R^2, R^3, R^4, and R^5 independently at each occurance represent H, SH, OR^{10}, halogen, $COOR^{10}$, $CONR^{11}R^{12}$, optionally substituted aryl, optionally substituted heterocyclyl, C_{4-14} cycloalkyl-C_{1-4} alkyl, C_{1-4} alkyl aryl, optionally substituted C_{1-14} straight chain, branched or cyclo alkyl, O-$(CH_2)_{2-6}$-NR^{10}-$(CH_2)_{0-3}$-R^{24}, $NR^{10}R^{24}$, $(CH_2)_{1-4}$-$NR^{33}R^{34}$, $(CH_2)_{1-4}$-$COOR^{33}$, O-$(CH_2)_{1-3}$-CO-het, O-$(CH_2)_{1-2}$-NH-CO-aryl, O-$(CH_2)_{1-2}$-NR^{10}-CO-$NR^{10}R^{33}$, O-$(CH_2)_{0-2}$-C(O)-$NR^{33}R^{34}$, O-$(CH_2)_{1-4}$-$COOR^{10}$, O-$(CH_2)_{1-3}$-het-R^{32}, O-optionally substituted cycloalkyl, O-$(CH_2)_{1-4}$-NR^{10}-COO-*t*-butyl, O-$(CH_2)_{1-4}$-$NR^{10}R^{33}$, O-$(CH_2)_{1-4}$-NR^{10}-C(O)-C_{0-3}-alkyl-optionally substituted aryl, O-substituted cycloalkyl, O-$(CH_2)_{0-6}$-optionally substituted aryl, $(CH_2)_{1-4}$-NH-C(O)O-$(CH_2)_{1-4}$-$PhR^{13}R^{14}$, NO_2, O-

$(CH_2)_{0-4}$-C(O)-NH-tetrahydro carboline, $NR^{10}R^{28}$, $O-(CH_2)_{1-3}$-optionally substituted het, CH_2COOCH_3, $CH=CH-COOCH_3$, 5-amidino benzimidazole,



, or



;

alternatively R^2 and R^3 taken together form



,



or



;

R^6 and R^9 independently at each occurance represents H, halogen, cyano, C_{1-4} alkyl, C_{1-4} halogenated alkyl, NO_2, O-aryl or OR^{11};

R^7 and R^8 independently at each occurance represent OH, CF_3, H, NO_2, C_{1-4} alkyl, OC_{1-4} alkyl, or O-aryl, halogen, cyano, or a basic group selected from guanidino, $C(=NH)N(R^{10})_2$, $C(=NH)-NH-NH_2$, $C(=O)NH_2$, 2-imidazoline, N-amidinomorpholine, N-amidino piperidine, 4-hydroxy-N-amidino piperidine, N-amidino pyrrolidine, tetrahydro pyrimidine, and thiazolidin-3-yl-methylideneamine; with the proviso that only one of R^7 and R^8 represent a basic group;

R^{10} independently at each occurance represents H, $(CH_2)_{0-2}$-aryl, C_{1-4} halo alkyl, or C_{1-14} straight chain, branched or cyclo alkyl, and alternatively, when one atom is substituted with two R^{10} groups, the atom along with the R^{10} groups can form a five to 10 membered ring structure;

R^{11} and R^{12} independently at each occurance represent H or C_{1-4} alkyl;

R^{20} represents R^{24}, C_{1-4}-alkyl, $(CH_2)_{1-3}$-biphenyl, $(CH_2)_{1-4}$-Ph-$N(SO_2-C_{1-2}\text{-alkyl})_2$, $(CH_2)_{1-4}$-NH-C(O)-R^{24}, $(CH_2)_{1-4}$-NH-SO_2-R^{24}, halogen, $COOR^{10}$, $(CH_2)_{1-4}$-Ph-$N(SO_2-C_{1-2}\text{alkyl})$, $(CH_2)_{1-4}$-NR^{10}-C(O)-R^{24}, $(CH_2)_{1-4}$-NR^{10}-SO_2-R^{24}, $(CH_2)_{1-4}$-het, $(CH_2)_{1-4}$-$CON(R^{10})_2$, $(CH_2)_{1-4}$-$N(R^{10})$-C(O)-$NR^{10}R^{24}$, $(CH_2)_{1-4}$-$N(R^{10})$-C(S)-$NR^{10}R^{24}$, or $(CH_2)_{1-3}$-COOH;

R^{24} represents R^{10}, $(CH_2)_{1-4}$-optionally substituted aryl, $(CH_2)_{0-4}OR^{10}$, CO-$(CH_2)_{1-2}$-$N(R^{10})_2$, $CO(CH_2)_{1-4}$-OR^{10}, $(CH_2)_{1-4}$-$COOR^{10}$, $(CH_2)_{0-4}$-$N(R^{10})_2$, SO_2R^{10}, COR^{10}, $CON(R^{10})_2$, $(CH_2)_{0-4}$-aryl-$COOR^{10}$, $(CH_2)_{0-4}$-aryl-$N(R^{10})_2$, or $(CH_2)_{1-4}$-het-aryl;

R^{28} represents $(CH_2)_{1-2}$-Ph-O-$(CH_2)_{0-2}$-het-R^{30}, C(O)-het, CH_2-Ph-CH_2-het-$(R^{30})_{1-3}$; $(CH_2)_{1-4}$-cyclohexyl-R^{31}, CH_2-Ph-O-Ph-$(R^{30})_{1-2}$, CH_2-(CH_2OH)-het-R^{30}, CH_2-Ph-O-cycloalkyl-R^{31}, CH_2-het-C(O)-CH_2-het-R^{30}, or CH_2-Ph-O-(CH_2)-O-het-R^{30};

R^{30} represents $SO_2N(R^{10})_2$, H, NHOH, amidino, or $C(=NH)CH_3$;

R^{31} represents R^{30}, amino-amidino, $NH-C(=NH)CH_3$ or R^{10};

R^{32} represents H, $C(O)-CH_2-NH_2$, or $C(O)-CH(CH(CH_3)_2)-NH_2$;

R^{33} and R^{34} independently at each occurance represent R^{10}, $(CH_2)_{0-4}$-Ar, optionally substituted aryl, $(CH_2)_{0-4}$ optionally substituted heteroaryl, $(CH_2)_{1-4}$-CN, $(CH_2)_{1-4}$-$N(R^{10})_2$, $(CH_2)_{1-4}$-OH, $(CH_2)_{1-4}$-SO_2-$N(R^{10})_2$;

alternatively, R^{33} and R^{34} along with the nitrogen atom that they are attached to forms a 4 to 14 atom ring structure selected from tetrahydro-1H-carboline; 6,7-Dialkoxyoxy-2-substituted 1,2,3,4-tetrahydro-isoquinoline,



or



;

R^{35} represents R^{10}, SO_2-R^{10}, COR^{10}, or $CONHR^{10}$;

E represents a bond, $S(O)_{0-2}$, O or NR^{10};

W_1, W_2, W_3 and W_4 independently represent C or N; and

Q, Q^1, Q^2, Q^3, L^1, L^2, L^3 and L^4 independently at each occurance represent N-natural or unnatural amino acid side chain, CHR^{10}, O, NH, $S(O)_{0-2}$, $N-C(O)-NHR^{10}$, $SO_2-N(R^{10})_2$, $N-C(O)-NH-(CH_2)_{1-4}-R^{26}$, NR^{10}, N-heteroaryl, $N-C(=NH)-NHR^{10}$, or $N-C(=NH)C_{1-4}$ alkyl;

R^{26} represents OH, NH_2, or SH;

provided that, (i) when R^1 = OH; R^7 = amidine; R^2, R^6, R^8, R^9, and R^{20} each represent H; and R^3, R^4, R^5 are independently chosen from H, CH_3, and halogen, then only one of R^3, R^4, and R^5 represents H; (ii) when R^1 = OH; R^7 = amidine; R^2, R^3, R^4, R^5, and R^{20} each represent H; and R^6, R^8, R^9 are independently chosen from H, CH_3, and halogen, then only one of R^6, R^8, and R^9 represents H; (iii) at least two of W_1, W_2, W_3 and W_4 represent C and at least one of W_1, W_2, W_3 and W_4 represent N; and (iv) when R^1 = OH; R^7 = amidine; and R^2, R^3, R^4, R^5,R^6, R^8,and R^9, represent H, R^{20} cannot be CH_3.

2. A compound of Formula I:

A-B

its prodrug forms, or pharmaceutically acceptable salts thereof, wherein

A represents



or



;

B represents



or



;

R^1 represents OH, halogen, COOH, $COO-C_{1-4}$ alkyl, $O-(CH_2)_{0-1}-Ph$, $N(R^{10})_2$, CH_2OR^{10}, C_{1-6} halogenated alkyl, $O-(CH_2)_{1-4}-CO-N(R^{10})_2$, SC_{1-4} alkyl, $NHSO_2C_{1-4}$alkyl, SO_2-OH, $O-SO_2-OH$, $O-SO_2-O-C_{1-4}$ alkyl, $OP(O)(OH)_2$, or OPO_3C_{1-4} alkyl;

R^2, R^3, R^4, and R^5 independently at each occurance represent H, SH, OR^{10}, halogen, $COOR^{10}$, $CONR^{11}R^{12}$, optionally substituted aryl, optionally substituted heterocyclyl, C_{4-14} cycloalkyl-C_{1-4} alkyl, C_{1-4} alkyl aryl, optionally substituted C_{1-14} straight chain, branched or cyclo alkyl, $O-(CH_2)_{2-6}-NR^{10}-(CH_2)_{0-3}-R^{24}$, $NR^{10}R^{24}$, $(CH_2)_{1-4}-NR^{33}R^{34}$, $(CH_2)_{1-4}-COOR^{33}$, $O-(CH_2)_{1-3}-CO-het$, $O-(CH_2)_{1-2}-NH-CO-aryl$, $O-(CH_2)_{1-2}-NR^{10}-CO-NR^{10}R^{33}$, $O-(CH_2)_{0-2}-C(O)-NR^{33}R^{34}$, $O-(CH_2)_{1-4}-COOR^{10}$, $O-(CH_2)_{1-3}-het-R^{32}$, O-optionally substituted cycloalkyl, $O-(CH_2)_{1-4}-NR^{10}-COO-t$-butyl, $O-(CH_2)_{1-4}-NR^{10}R^{33}$, $O-(CH_2)_{1-4}-NR^{10}-C(O)-C_{0-3}$-alkyl-optionally substituted aryl, O-substituted cycloalkyl, $O-(CH_2)_{0-6}$-optionally substituted aryl, $(CH_2)_{1-4}-NH-C(O)O-(CH_2)_{1-4}-PhR^{13}R^{14}$, NO_2, $O-(CH_2)_{0-4}-C(O)-NH$-tetrahydro carboline, $NR^{10}R^{28}$, $O-(CH_2)_{1-3}-$ optionally substituted het, CH_2COOCH_3, $CH=CH-COOCH_3$, 5-amidino benzimidazole,



, or



;

alternatively R^2 and R^3 taken together form



;

R^6 and R^9 independently at each occurance represents H, halogen, cyano, C_{1-4} alkyl, C_{1-4} halogenated alkyl, NO_2, O-aryl or OR^{11};

R^7 and R^8 independently at each occurance represent OH, CF_3, H, NO_2, C_{1-4} alkyl, OC_{1-4} alkyl, or O-aryl, halogen, cyano, or a basic group selected from guanidino, $C(=NH)N(R^{10})_2$, $C(=NH)-NH-NH_2$, $C(=O)NH_2$, 2-imidazoline, N-amidinomorpholine, N-amidino piperidine, 4-hydroxy-N-amidino piperidine, N-amidino pyrrolidine, tetrahydro pyrimidine, and thiazolidin-3-yl-methylideneamine; with the proviso that only one of R^7 and R^8 represent a basic group;

R^{10} independently at each occurance represents H, $(CH_2)_{0-2}$-aryl, C_{1-4} halo alkyl, or C_{1-14} straight chain, branched or cyclo alkyl, and alternatively, when one atom is substituted with two R^{10} groups, the atom along with the R^{10} groups can form a five to 10 membered ring structure;

R^{11} and R^{12} independently at each occurance represent H or C_{1-4} alkyl;

R^{20} represents R^{24}, C_{1-4}-alkyl, $(CH_2)_{1-3}$-biphenyl, $(CH_2)_{1-4}$-Ph-$N(SO_2-C_{1-2}$-alkyl$)_2$, $(CH_2)_{1-4}-NH-C(O)-R^{24}$, $(CH_2)_{1-4}-NH-SO_2-R^{24}$, halogen, $COOR^{10}$, $(CH_2)_{1-4}$-Ph-$N(SO_2-C_{1-2}$alkyl$)$, $(CH_2)_{1-4}-NR^{10}-C(O)-R^{24}$, $(CH_2)_{1-4}-NR^{10}-SO_2-R^{24}$, $(CH_2)_{1-4}$-het, $(CH_2)_{1-4}-CON(R^{10})_2$, $(CH_2)_{1-4}-N(R^{10})-C(O)-NR^{10}R^{24}$, $(CH_2)_{1-4}-N(R^{10})-C(S)-NR^{10}R^{24}$, or $(CH_2)_{1-3}-COOH$;

R^{24} represents R^{10}, $(CH_2)_{1-4}$-optionally substituted aryl, $(CH_2)_{0-4}OR^{10}$, $CO-(CH_2)_{1-2}-N(R^{10})_2$, $CO(CH_2)_{1-4}-OR^{10}$, $(CH_2)_{1-4}-COOR^{10}$, $(CH_2)_{0-4}-N(R^{10})_2$, SO_2R^{10}, COR^{10}, $CON(R^{10})_2$, $(CH_2)_{0-4}$-aryl-$COOR^{10}$, $(CH_2)_{0-4}$-aryl-$N(R^{10})_2$, or $(CH_2)_{1-4}$-het-aryl;

R^{28} represents $(CH_2)_{1-2}$-Ph-O-$(CH_2)_{0-2}$-het-R^{30}, C(O)-het, CH_2-Ph-CH_2-het-$(R^{30})_{1-3}$; $(CH_2)_{1-4}$-cyclohexyl-R^{31}, CH_2-Ph-O-Ph-$(R^{30})_{1-2}$,

CH_2-(CH_2OH)-het-R^{30}, CH_2-Ph-O-cycloalkyl-R^{31}, CH_2-het-C(O)-CH_2-het-R^{30}, or CH_2-Ph-O-(CH_2)-O-het-R^{30};

R^{30} represents $SO_2N(R^{10})_2$, H, NHOH, amidino, or C(=NH)CH_3;

R^{31} represents R^{30}, amino-amidino, NH-C(=NH)CH_3 or R^{10};

R^{32} represents H, C(O)-CH_2-NH_2, or C(O)-CH(CH(CH_3)$_2$)-NH_2;

R^{33} and R^{34} independently at each occurance represent R^{10}, $(CH_2)_{0-4}$-Ar, optionally substituted aryl, $(CH_2)_{0-4}$ optionally substituted heteroaryl, $(CH_2)_{1-4}$-CN, $(CH_2)_{1-4}$-$N(R^{10})_2$, $(CH_2)_{1-4}$-OH, $(CH_2)_{1-4}$-SO_2-$N(R^{10})_2$;

alternatively, R^{33} and R^{34} along with the nitrogen atom that they are attached to forms a 4 to 14 atom ring structure selected from tetrahydro-1H-carboline; 6,7-Dialkoxyoxy-2-substituted 1,2,3,4-tetrahydro-isoquinoline,



or



;

R^{35} represents R^{10}, SO_2-R^{10}, COR^{10}, or $CONHR^{10}$;

E represents a bond, $S(O)_{0-2}$, O or NR^{10};

W_1, W_2, W_3 and W_4 independently represent C or N; and

Q, Q^1, Q^2, Q^3, L^1, L^2, L^3 and L^4 independently at each occurance represent N-natural or unnatural amino acid side chain, CHR^{10}, O, NH, $S(O)_{0-2}$, N-C(O)-NHR^{10}, SO_2-$N(R^{10})_2$, N-C(O)-NH-(CH_2)$_{1-4}$-R^{26}, NR^{10}, N-heteroaryl, N-C(=NH)-NHR^{10}, or N-C(=NH)C_{1-4} alkyl;

R^{26} represents OH, NH_2, or SH;

provided that, (i) when R^1 = OH; R^7 = amidine; R^2, R^6, R^8, R^9, and R^{20} each represent H; and R^3, R^4, R^5 are independently chosen from H, CH_3, and halogen, then only one of R^3, R^4, and R^5 represents H; (ii) when R^1 = OH; R^7 = amidine; R^2, R^3, R^4, R^5, and R^{20} each represent H; and R^6, R^8, R^9 are independently chosen from H, CH_3, and halogen, then only one of R^6, R^8, and R^9 represents H; (iii) at least two of

W_1, W_2, W_3 and W_4 represent C and at least one of W_1, W_2, W_3 and W_4 represent N; and (iv) when R^1 = OH; R^7 = amidine; and R^2, R^3, R^4, R^5, R^6, R^8, and R^9, represent H, R^{20} cannot be CH_3.

3. A compound of Claim 2 wherein
A represents



or



;

R^1 represents OH, O-Ph, COOH, or $P(O)(OH)_2$;
R^7 represents H, Br, $CONH_2$, CN, $C(=NH)-NH-NH_2$, $NH-C(=NH)-NH_2$ or $C(=NH)-NH_2$;
R^{20} represents H, C_{1-2} alkyl, $(CH_2)_{1-4}$-optionally substituted aryl, $(CH_2)_{1-4}$-het; $(CH_2)_{1-4}-N(R^{10})_2$, $(CH_2)_{1-4}-CON(R^{10})_2$, $(CH_2)_{1-4}-NR^{10}-C(O)-R^{24}$, $(CH_2)_{1-4}-NR^{10}-SO_2-R^{24}$, or $(CH_2)_{1-3}-COOH$;
X and Y independently at each occurance are selected from NH, N, C, or CH, such that at least one of X and Y always represents N or NH ; and
Z represents C or N;
provided that, (i) when Z represents N, R^7 represents H or $C(=NH)NH_2$.

4. A compound of claim 3 wherein
A represents



;

and

B represents



, and

X and Y represent N; and

R^7 represents $-CONH_2$, or $C(=NH)-NH_2$;

5. A compound of claim 4 wherein

R^1 represents OH, -COOH, and $O-P(O)(OH)_2$;

R^2 and R^3 independently represent halogen, H, C_{1-4} alkyl, Ph, toluyl, OH, $O-(CH_2)_{1-3}-C(O)-NH-(CH_2)_{1-2}-CN$, $O-(CH_2)_{1-3}-Ph-p-OCH_3$, $O-CH_2-C(O)-NH-(CH_2)_{1-2}-CH-(CH_3)_2$, $O-CH_2-C(O)-NH-(CH_2)-Ph$, $O-CH_2-C(O)-NH-(CH_2)-Ph-pCH_3$, $O-C_{1-3}$ alkyl, $O-(CH_2)_{0-2}-Ph-R^{10}$, $O-CH_2-C(O)-NH-(CH_2)_2-H$, $Ph-C_{1-3}$ alkyl, $Ph-N(R^{10})_2$, $O-(CH_2)_{1-3}$-het, $O-(CH_2)_{1-3}-Ph$-halo, $O-(CH_2)_{1-3}-NHSO_2Ph-R^{10}$, $O-(CH_2)_{1-3}-NHCO-(CH_2)_{0-2}-Ph$, $O-CH_2-C(O)-NH-CH_2-COO-C(CH_3)_3$, $O-(CH_2)_2-NHC(O)-CH_2-NH_2$, -OPh, $O-(CH_2)_{1-3}$-NH-het, $O-(CH_2)_2-NH-C(O)$-pyridyl, $O-(CH_2)_2-NH-C(O)-NH$-benzyl, $O-(CH_2)_2$-cyclohexyl, $O-(CH_2)_2-NH-C(O)-(CH_2)_2-CONH_2$, $O-(CH_2)_2-NH-C(O)-CH_2-OCH_3$, thiophene, pyridyl, or $O-(CH_2)_2$-pyridyl;

alternatively R^2 and R^3 taken together form



R^4 represents halogen, H, NO_2, C_{1-2}-alkyl, CH=CH-$COOCH_3$, $NHSO_2C_{1-2}$ alkyl, NHCO-het, $(CH_2)_{1-3}$-$COOR^{10}$, $(CH_2)_{1-3}$-CONH-$(CH_2)_{1-3}$-pyridyl, or $(CH_2)_{1-3}$-CONH-$(CH_2)_{1-3}$-dichlorophenyl;

R^5 represents H;

R^6 represents H;

R^7 represents C(=NH)-NH_2 or NH(=NH)NH_2;

R^8 represents H, halogen, OR^{10}, CF_3, or C(=NH)-NH_2;

R^9 represents H or halogen; and

R^{20} represents H.

6. A compound of claim 2 wherein

A represents



;

and

B represents



, and

X and Y represent N.

7. A compound of claim 6 wherein

R^1 represents OH, or COOH;

R^2 represents H, halogen, OH, phenyl, $O-(CH_2)_{1-3}-Ph$, imidazolyl, 5-amidino benzimidazolyl, $O-(CH_2)_{1-2}-C(O)-NH-C_{1-6}$ alkyl, or $O-CH_2-C(O)-NH-CH_2-Ph$;

R^3 represents H, $O-CH_2-COOH$, $O-CH_2-C(O)O-C_2H_5$, $O-CH_2-C(O)-NH-(CH_2)_{1-4}$-aryl, $O-(CH_2)_{1-4}-NH-C(O)$-naphthyl, $CONH_2$, $O-(CH_2)_{1-2}-C(O)N(R^{10})-(CH_2)_{1-3}-Ph-R^{13}R^{14}$, $O-CH_2-C(O)-N(R^{10})-CH_2$-piperanyl, $O-CH_2-C(O)-NH-CH_2$-indoyl, $(CH_2)_{0-4}$-aryl,



,



,



,



, or



;

R^4 represents H, $-CH_3$, halogen, $-OCH_3$, $-(CH_2)_{1-2}COOR^{10}$, $-COOH$, $-NO_2$, $-OH$, aryl,



R^5 represents H;

R^6 represents H;

R^7 represents H, halogen, $-C(O)-NH_2$, $-C(=NH)-NH_2$;

R^8 represents H, Cl, F, OH or OCH_3;

R^9 represents H;

R^{13} and R^{14} independently at each occurance represents H, halogen, $-OC_{1-2}$ alkyl, -OH, $-CF_3$, or $-C_{1-4}$ alkyl; and

R^{15} represents H,



R^{20} represents H or $-CH_2-Ph$.

8. A compound of claim 2, wherein the compound is selected from

3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-N-phenethyl-propionamide;
3-[4-(6-Carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenyl]-N-(2,3-dichloro-benzyl)-propionamide;
2-[4-(6-Carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-N-(2,3-dichloro-benzyl)-acetamide;
3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-N-[2-(2,4-dichloro-phenyl)-ethyl]-propionamide;
3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-N-(2-pyridin-2-yl-ethyl)-propionamide;
3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-N-(3-phenyl-propyl)-propionamide;
2-[4-(6-Carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-N -naphthalen-1-ylmethyl-acetamide;
2-(3'-Amino-5-chloro-2-hydroxy-biphenyl-3-yl)-3H-benzoimidazole-5-carboxamidine;
3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-propionic acid;
2-(3,5-Bis-hydroperoxy-2-hydroxy-phenyl)-3H-benzoimidazole-5-carboxamidine;
2-[4-(5-Carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-N-(3-chloro-benzyl)-acetamide;
N-Benzyl-3-[3-bromo-5-(6-carbamimidoyl-1H-benzoimidazol -2-yl)-4-hydroxy-phenyl]-propionamide;
2-(3,5-Dibromo-2,4-dihydroxy-phenyl)-3H-benzoimidazole-5-carboxamidine;
2-(2-Hydroxy-biphenyl-3-yl)-3H-benzoimidazole-5-carboxamidine;
2-(5-Chloro-2-hydroxy-biphenyl-3-yl)-3H-benzoimidazole-5-carboxamidine;
2-(2-Hydroxy-3-phenethyloxy-phenyl)-3H-benzoimidazole-5-carboxamidine;
N-(3-Bromo-benzyl)-2-[4-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-acetamide;
2-{3-[1-(3-Amino-propionyl)-pyrrolidin-2-ylmethoxy]-2-hydroxy-phenyl}-3H-benzoimidazole-5-carboxamidine;

2-(5-Chloro-2-hydroxy-3-pyridin-3-yl-phenyl)-1H-benzoimidazole-5-carboxamidine;
2-[3-(5-Carbamimidoyl-1H-benzoimidazol-2-yl)-2-hydroxy-phenyl]-3,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxamidine;
2-[3-(1-Aminoacetyl-pyrrolidin-2-ylmethoxy)-2-hydroxy-phenyl]-3H-benzoimidazole-5-carboxamidine; and
2-(2-Hydroxy-3-phenoxy-phenyl)-3H-benzoimidazole-5-carboxamidine;
2-[2-Hydroxy-3-(1-methyl-1H-benzoimidazol-2-yl)-phenyl]-1H-benzoimidazole-5-carboxamidine;
2-[3-(1-Aminoacetyl-piperidin-3-ylmethoxy)-2-hydroxy-phenyl]-1H-benzoimidazole-5-carboxamidine;
2-{3-[1-(2-Amino-3-methyl-butyryl)-pyrrolidin-2-ylmethoxy]-2-hydroxy-phenyl}-1H-benzoimidazole-5-carboxamidine;
2-[2-Hydroxy-3-(1-hydroxyacetyl-pyrrolidin-2-ylmethoxy)-phenyl]-1H-benzoimidazole-5-carboxamidine;
2-(2-Hydroxy-5-iodo-3-methoxy-phenyl)-1H-benzoimidazole-5-carboxamidine;
2-{3-[1-(2-Amino-3-methyl-butyryl)-pyrrolidin-2-ylmethoxy]-2-hydroxy-phenyl}-3H-benzoimidazole-5-carboxamidine;
2-(2-Hydroxy-5-{4-[1-(1-imino-ethyl)-piperidin-4-yloxy]-benzylamino}-phenyl)-3H-benzoimidazole-5-carboxamidine; compound with methane;
2-(2-Hydroxy-5-{4-[1-(1-imino-ethyl)-piperidin-3-ylmethoxy]-benzylamino}-phenyl)-3H-benzoimidazole-5-carboxamidine;
2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3H-benzoimidazole-5-carboxamidine;
3-[2,6-Dibromo-4-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-propionic acid;
3-[2,6-Dibromo-4-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-propionic acid ethyl ester; and
2-[3-Bromo-2-hydroxy-5-(3-methoxy-but-3-enyl)-phenyl]-3H-benzoimidazole-5-carboxamidine;
or a stereoisomer or pharmaceutically acceptable salt form thereof.

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 2 or a pharmaceutically acceptable salt thereof.

11. A method for treating or preventing a thromboembolic disorder, comprising administering t a patient in need thereof a therapeutically effective amount of a compound according to Claim 2 or a pharmaceutically acceptable salt thereof.

12. A compound of Claim 2 wherein A represents



;

B represents



;

X represents C; and

Y represents NH.

13. A compound of claim 12 wherein
R^1 represents -OH, -COOH, or $P(O)(OH)_2$;
R^2 represents H, halogen, R^{10}, -aryl, heteroaryl, $-C_{1-2}$-alkyl, COOH, $-OC_{1-2}$-alkyl, $-O-(CH_2)_{0-2}$-aryl, or $-C_{6-10}$ aryl-C_{1-4} alkyl;
R^3 represents H or $-O-(CH_2)_{1-3}-COOH$;
alternatively R^2 and R^3 taken together represent



;
R^4 represents H, $-C_{1-4}$ alkyl, $-(CH_2)_{1-4}-COOH$, $-(CH_2)_{1-4}-COOC_{1-2}$-alkyl, halogen, $-(CH_2)_{1-2}-CONH_2$, $-CONH_2$, $-NO_2$, $-O-C_{1-2}$ alkyl, or -OH;
R^5 represents H, $-C_{1-3}$ alkyl, $-(CH_2)_{1-4}-C(O)-NH-(CH_2)_{1-3}$-heteroaryl, $-(CH_2)_{1-4}-C(O)-NH-CH_3$, or -COOH;
R^6 represents H, halogen, or $-C_{1-3}$ alkyl;
R^7 represents $-C(O)-NH_2$, $-C(=NH)-NH-NH_2$, or amidino;
R^8 represents H, or halogen; and
R^{20} represents H, $-(CH_2)_{1-4}-Ph-N(SO_2-C_{1-2}alkyl)$, $-(CH_2)_{1-4}-NR^{10}-C(O)-R^{24}$, $-(CH_2)_{1-4}-NR^{10}-SO_2-R^{24}$, $-(CH_2)_{1-4}$-het, $-(CH_2)_{1-4}-CON(R^{10})_2$, $-(CH_2)_{1-4}-N(R^{10})-C(O)-NR^{10}R^{24}$, $-(CH_2)_{1-2}-Ph-NH_2$, $-(CH_2)_{1-2}-Ph-NO_2$, $-(CH_2)_{1-4}-N(R^{10})-C(S)-NR^{10}R^{24}$, $-C_{1-2}$-alkyl, $-(CH_2)_{1-4}$-optionally substituted aryl, $-(CH_2)_{1-4}$-het; $-(CH_2)_{1-3}-N(R^{10})_2$; $-(CH_2)_{1-4}-CON(R^{10})_2$, or $-(CH_2)_{1-3}-COOH$.

14. A compound of claim 13 wherein the compound is selected from
3-Benzyl-2-(3-chloro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
3-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-propionic acid;
[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-acetic acid;
6-Chloro-2-(3,5-dichloro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;

3-Bromo-5-(5-carbamimidoyl-1H-indol-2-yl)-4-hydroxy-benzamide;
2-(3,5-Dichloro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
3-(4-Amino-benzyl)-2-(3-bromo-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
2-(2-Hydroxy-biphenyl-3-yl)-1H-indole-5-carboxamidine;
2-(3-Bromo-2-hydroxy-5-nitro-phenyl)-1H-indole-5-carboxamidine;
2-(5-Hydroxy-2,3-dihydro-benzo[1,4]dioxin-6-yl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(3,5-difluoro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(3,5-dibromo-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
[3-Bromo-5-(5-carbamimidoyl-1H-indol-2-yl)-4-hydroxy-phenyl]-acetic acid;
3-Benzyl-2-(5-chloro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
2-[3-Bromo-5-(5-carbamimidoyl-1H-indol-2-yl)-4-hydroxy-phenyl]-acetamide;
2-(3,5-Difluoro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
2-(3,5-Dibromo-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;
2-(2-Hydroxy-5-methyl-biphenyl-3-yl)-1H-indole-5-carboxamidine;
2-(2-Hydroxy-5,4'-dimethyl-biphenyl-3-yl)-1H-indole-5-carboxamidine;
2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(3-bromo-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(3-chloro-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(2-hydroxy-3,5-dimethyl-phenyl)-1H-indole-5-carboxamidine;

2-(3,5-Dibromo-2-hydroxy-phenyl)-3-methyl-1H-indole-5-carboxamidine;
2-(2-Hydroxy-5-methyl-3-thiophen-2-yl-phenyl)-1H-indole-5-carboxamidine;
2-[2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-5-carbamimidoyl-1H-indol-3-yl]-acetamide;
[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-acetic acid methyl ester;
3-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-propionic acid methyl ester;
3-(3-Amino-benzyl)-2-(3-bromo-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3-(3-nitro-benzyl)-1H-indole-5-carboxamidine;
3-(3-Amino-benzyl)-2-(2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
3-Benzyl-2-(3-chloro-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;
6-Chloro-2-{5-[2-(1,1-dioxo-1-thiomorpholin-4-yl)-2-oxo-ethyl]-2-hydroxy-biphenyl-3-yl}-1H-indole-5-carboxamidine;
2-[5-(5-Carbamimidoyl-6-chloro-1H-indol-2-yl)-6-hydroxy-biphenyl-3-yl]-N-(2-piperidin-1-yl-ethyl)-acetamide;
6-Chloro-2-{2-hydroxy-5-[2-(2-methoxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-biphenyl-3-yl}-1H-indole-5-carboxamidine;
6-Chloro-2-{2-hydroxy-5-[2-oxo-3-(tetrahydro-furan-2-yl)-propyl]-biphenyl-3-yl}-1H-indole-5-carboxamidine;
2-[5-(5-Carbamimidoyl-6-chloro-1H-indol-2-yl)-6-hydroxy-biphenyl-3-yl]-N-(tetrahydro-furan-2-ylmethyl)-acetamide;
2-[5-(5-Carbamimidoyl-6-chloro-1H-indol-2-yl)-6-hydroxy-biphenyl-3-yl]-N-(3-methoxy-propyl)-acetamide;
Morpholine-4-carboxylic acid {2-[5-(5-carbamimidoyl-6-chloro-1H-indol-2-yl)-6-hydroxy-biphenyl-3-yloxy]-ethyl}-amide;
Phosphoric acid mono-{2-[3-(3-benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-ethyl} ester;

2-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-N-{4-[1-(1-imino-ethyl)-piperidin-4-yloxy]-phenyl}-acetamide;

4-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-butyric acid;

2-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-acetamide;

2-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-N,N-dimethyl-acetamide;

[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-acetic acid;

3-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-pentanedioic acid bis-[(2-morpholin-4-yl-ethyl)-amide];

3-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-propionamide; and

2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3-(4-nitro-benzyl)-1H-indole-5-carboxamidine;

or a stereoisomer or pharmaceutically acceptable salt form thereof.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 12 or a pharmaceutically acceptable salt thereof.

16. A method for treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 12 or a pharmaceutically acceptable salt thereof.